His primary areas of investigation include Internal medicine, Transplantation, Surgery, Immunology and Multiple myeloma. His Internal medicine research incorporates elements of Gastroenterology and Oncology. He is interested in Hematopoietic stem cell transplantation, which is a field of Transplantation.
His study in Surgery is interdisciplinary in nature, drawing from both Tolerability, Dexamethasone and Hazard ratio. Much of his study explores Immunology relationship to Virology. The various areas that he examines in his Multiple myeloma study include Adverse effect, Immunopathology and Clinical trial.
The scientist’s investigation covers issues in Internal medicine, Multiple myeloma, Immunology, Transplantation and Oncology. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Surgery. Immunotherapy is closely connected to Cancer research in his research, which is encompassed under the umbrella topic of Multiple myeloma.
His is involved in several facets of Immunology study, as is seen by his studies on Immune system, T cell, Antigen, Aspergillus fumigatus and CD8. Hematopoietic stem cell transplantation is the focus of his Transplantation research. His work in Oncology covers topics such as Myeloid leukemia which are related to areas like Leukemia.
Hermann Einsele mostly deals with Multiple myeloma, Internal medicine, Oncology, Cancer research and Transplantation. His work focuses on many connections between Multiple myeloma and other disciplines, such as Clinical trial, that overlap with his field of interest in Intensive care medicine. His Hematology, Dexamethasone, Myeloid leukemia and Hematopoietic stem cell transplantation study in the realm of Internal medicine interacts with subjects such as In patient.
Hermann Einsele combines subjects such as Refractory, Elotuzumab, Monoclonal antibody, Daratumumab and Refractory Multiple Myeloma with his study of Oncology. His Cancer research research includes themes of Cell culture, Point mutation, Antigen, Leukemia and Immunotherapy. His work deals with themes such as Stem cell and Immunology, which intersect with Transplantation.
Hermann Einsele mainly investigates Multiple myeloma, Internal medicine, Oncology, Transplantation and Cancer research. Hermann Einsele interconnects Hematology, Clinical trial, Disease and Adverse effect in the investigation of issues within Multiple myeloma. His Lenalidomide, Dexamethasone, Hazard ratio and Hematopoietic stem cell transplantation study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines.
His Oncology research integrates issues from Young adult, Blinatumomab, Monoclonal antibody and Lymphoma. Hermann Einsele has researched Transplantation in several fields, including Treatment options, Stem cell and Fdg pet ct. His Cancer research research is multidisciplinary, incorporating perspectives in Point mutation, Downregulation and upregulation, CXCR4 and Immunotherapy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.
Marcie Tomblyn;Tom Chiller;Hermann Einsele;Ronald Gress.
Biology of Blood and Marrow Transplantation (2009)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo.
The New England Journal of Medicine (2015)
Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp;Peter Kufer;Nicola Gökbuget;Mariele Goebeler.
Journal of Clinical Oncology (2011)
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Ralf Bargou;Eugen Leo;Gerhard Zugmaier;Matthias Klinger.
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy.
Hermann Einsele;Eddy Roosnek;Nathalie Rufer;Christian Sinzger.
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac.
Lancet Oncology (2014)
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer
Volker Heinemann;Detlef Quietzsch;Frank Gieseler;Michael Gonnermann.
Journal of Clinical Oncology (2006)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Roswitha Forstpointner;Michael Unterhalt;Martin Dreyling;Hans-Peter Böck.
The landscape of genomic alterations across childhood cancers
Susanne N. Gröbner;Barbara C. Worst;Joachim Weischenfeldt;Joachim Weischenfeldt;Ivo Buchhalter.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: